Compare Knight-Swift Transportation Holdings Inc. (KNX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Knight-Swift Transportation Holdings Inc. vs Tango Therapeutics Inc. — how do they compare? Knight-Swift Transportation Holdings Inc. trades at $63.5 (market cap $10.26B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Knight-Swift Transportation Holdings Inc. is far larger — about 2.7× Tango Therapeutics Inc.'s market cap, and Knight-Swift Transportation Holdings Inc. pays a 1.27% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Knight-Swift Transportation Holdings Inc. for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| KNX | TNGX | |
|---|---|---|
Market Cap | $10.26B | $3.75B |
Volume | 4,530,077 | 9,619,106 |
Sector | Industrials | Health |
52-Week High | $82.45 | $32.90 |
52-Week Low | $41.68 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.75B | $2.77B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Knight-Swift Transportation (KNX) trades at $63.01, down 2.34% with bearish technical signals. The company reported mixed earnings with Q2 2026 beating estimates but Q4 2025 missing expectations. Revenue trends show modest growth to $7.7B in 2026, though net income margin compression to 0.55% raises concerns. Analyst consensus remains strongly bullish with 64% buy ratings and $85.75 price target, while technical indicators show selling pressure with support at $63.
The stock presents a divergence between strong Wall Street optimism and current technical weakness. Upside potential exists from truckload margin improvements and capacity-driven freight recovery, but risks include margin pressure, CEO stock sales, and broader transportation sector volatility. The upcoming Q3 2026 earnings report on October 21, 2026 will be critical for validating the bullish analyst thesis.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Knight-Swift Transportation Holdings Inc.
Knight-Swift provides truckload, less-than-truckload, logistics, and freight management services. It operates a large transportation network across North America.
Read more on KNX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
